2008-07-17 13:17:00
SAN DIEGO–(EMWNews)–Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that Martin
C. Muenchbach, Ph.D., an Investment Manager at Bellevue Asset Management
AG, has notified the Company that he will be stepping down from his
position as a member of the Board of Directors as of August 1, 2008. Dr.
Muenchbach joined the Board in December 2005, advising Optimer as a
private company and then working with the Company in its transition to a
public company. Dr. Muenchbach’s departure is
not related to relations with the board members or with the company. Dr.
Muenchbach will continue to follow his pursuits in venture capital,
serving on the Board of many privately held companies. Optimer is
currently in the process of identifying candidates to serve on its Board
of Directors.
“We would like to thank Martin for his many
contributions and dedicated service to the Company. His board experience
and leadership have been invaluable as the company has grown from a
private company through its maturation as a public company,” said
Michael N. Chang, Ph.D., CEO and President of Optimer. “We
wish him great success in his future endeavors.”
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on
discovering, developing and commercializing innovative anti-infective
products for the treatment of serious infections. Optimer has two
late-stage anti-infective product candidates. OPT-80, currently in two
pivotal Phase 3 clinical trials, is being developed for the treatment of Clostridium
difficile infection, the most common hospital-acquired diarrhea.
Prulifloxacin, also in two pivotal Phase 3 clinical trials, is an
antibiotic being developed for the treatment of travelers’
diarrhea, a form of infectious diarrhea. Additional information
regarding Optimer can be found at http://www.optimerpharma.com.
Forward-looking Statements
Statements included in this press release that are not a description of
historical facts are forward-looking statements, including without
limitation all statements related to the anticipated resignation of
current directors and the identification of additional directors. Words
such as “believes”, “anticipates”, “plans”, “expects”, “may”,
“intend”, “will”, “goal” and similar expressions are intended to
identify forward-looking statements. The inclusion of forward-looking
statements should not be regarded as a representation by Optimer that
any of its plans will be achieved. Actual results may differ materially
from those set forth in this release due to the risks and uncertainties
inherent in Optimer’s business including, without limitation, the risks
detailed in Optimer’s filings with the Securities and Exchange
Commission.
Optimer Pharmaceuticals, Inc. Communications Manager Finance I. Spark, Account Director |
|
Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89
Get Unlimited Organic Website Traffic to your Website
TheNFG.com now offers Organic Lead Generation & Traffic Solutions